Insulet Corporation (PODD)
| Market Cap | 15.15B |
| Revenue (ttm) | 1.56B |
| Net Income (ttm) | 120.00M |
| Shares Out | 69.83M |
| EPS (ttm) | 1.72 |
| PE Ratio | 126.15 |
| Forward PE | 94.18 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 524,182 |
| Open | 218.77 |
| Previous Close | 219.43 |
| Day's Range | 215.89 - 219.80 |
| 52-Week Range | 125.82 - 335.91 |
| Beta | 0.98 |
| Analysts | Buy |
| Price Target | 265.87 (+22.53%) |
| Earnings Date | Feb 22, 2024 |
About PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorpo... [Read more]
Financial Performance
In 2022, Insulet's revenue was $1.31 billion, an increase of 18.79% compared to the previous year's $1.10 billion. Earnings were $4.60 million, a decrease of -72.62%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for PODD stock is "Buy." The 12-month stock price forecast is $265.87, which is an increase of 22.53% from the latest price.
News
3 Medical-Device Stocks Could Click in 2024
Baird is bullish on Boston Scientific, Insulet, and DexCom, stocks set to benefit as those companies ramp up sales.
Salesforce, Insulet, and Datadog Are November's Top Performers—and These Are the Worst
Salesforce is the Dow Jones Industrial Average's top-performing stock in November, while Cisco is the worst.
Insulet to Present at Upcoming Investor Conferences
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management ...
Earnings-season winners: 20 companies that have grown sales while improving profit margins
Earnings season is a time when investors like to see a “beat and raise” pattern. That is, companies report sales and earnings that surprise the market by coming in ahead of analysts' estimates.
Insulet (PODD) stock up 14% on positive earnings and growth forecast
Shares of medical device company Insulet Corporation (NASDAQ: PODD) witnessed a remarkable surge, jumping by 14% on Friday in response to the company's recent earnings report. The substantial increase...
Insulet Stock Rallies on Revenue Boost. It's a 'Misunderstood Growth Name.
The automated insulin technology developer posts third-quarter revenue of $432.7 million, compared with $340.8 million a year earlier.
Insulet shares rebound after results top estimates
Insulet Corp. shares PODD, +1.98% climbed 10% premarket on Friday after the insulin pump maker late Thursday reported third-quarter results that beat expectations and aimed to dispel some investor fea...
Insulet lifts sales growth forecast on resilient demand for insulin pumps
Insulet Corp on Thursday raised its full-year revenue growth forecast after posting strong third-quarter sales, banking on strong demand for its tubeless insulin pumps.
Insulet Reports Third Quarter 2023 Revenue Increase of 27% Year-Over-Year (25% Constant Currency1)
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced f...
Insulet Spotlights Diabetes Awareness on World Diabetes Day and Throughout November
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced a...
Diabetes stocks jump as obesity-drug recovery comes ahead of schedule, analysts say
Diabetes-device makers' stocks are breaking out of ‘GLP-1 jail' ahead of schedule, analysts say, after months of stock-market punishment based on fears that the popular obesity drugs would clobber the...
The weight-loss drugs are coming for these companies — but here's why Coke, others, may be spared, says JPMorgan
Citing Vanda Research, the Wall Street Journal reports that the average individual-investor stock portfolio is up 150% since the start of 2014, versus around 140% for the S&P 500's SPX during the same...
Insulet Announces FDA 510(k) Clearance of the Omnipod® 5 App for iPhone
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
What other industries could weight loss drugs disrupt?
Jared Holz, Mizuho health care sector strategist, joins the ‘Fast Money' traders to discuss Novo Nordisj's kidney trial outcomes and the impact of weight loss drugs on the health care sector.
Diabetes-related stocks take hit over weight loss drug craze
This segment originally aired on October 5, 2023 Weight loss drugs, like Novo Nordisk's (NVO) Ozempic, have become popular across healthcare providers in regard to diabetes treatment. Although use is ...
Are the S&P 500's Biggest Q3 Losers Next Year's Winners?
What started out to be a promising third quarter for U.S. stocks turned into a dud. On the backs of artificial intelligence (AI) excitement, the S&P 500 stormed out of the gates in July only to trend ...
Insulet CFO to step down to join 3M's healthcare business
Insulet Corp said on Tuesday Wayde McMillan would step down as the medical device maker's chief financial officer, effective Oct. 20, to join 3M's healthcare business.
Insulet Announces CFO Transition
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...
New weight loss drugs could mean a $25 billion drag on restaurants by 2025, says Mizuho's Dan Dolev
Matt Taylor, Jefferies analyst, and Dan Dolev, managing director at Mizuho Securities, join 'The Exchange' to discuss how new weight loss drugs could decline revenue for restaurant transaction platfor...
These 10 stocks in the S&P 500 are expected to soar after rising interest rates have pushed down valuations
Two things investors can be sure about: Nothing lasts forever and the stock market always overreacts. The spiking of yields on long-term U.S. Treasury securities has been breathtaking, and it has led ...
SolarEdge, Insulet, and Dollar General Lead S&P 500 Q3 Losses
SolarEdge Technologies Inc. (SEDG), Insulet Corp. (PODD), and Dollar General Corp. (DG) were the steepest S&P 500 stock decliners in the third quarter as the index lost 3.65%.
Weight-Loss-Drug Stock Sting May Be Easing for Device Makers
Wall Street says insulin pump maker Insulet and Tandem Diabetes, as well as glucose-monitor maker DexCom, look ready to rise after pressure from Novo Nordisk's Wegovy and Eli Lilly.